Peapod Lane Capital LLC Takes Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Peapod Lane Capital LLC purchased a new position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 445,744 shares of the company's stock, valued at approximately $673,000. Peapod Lane Capital LLC owned about 0.86% of PMV Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in PMV Pharmaceuticals in the third quarter worth $42,000. M&T Bank Corp boosted its holdings in shares of PMV Pharmaceuticals by 54.6% in the 3rd quarter. M&T Bank Corp now owns 399,548 shares of the company's stock worth $596,000 after purchasing an additional 141,064 shares in the last quarter. ArrowMark Colorado Holdings LLC increased its position in shares of PMV Pharmaceuticals by 30.0% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 3,647,291 shares of the company's stock valued at $5,434,000 after purchasing an additional 842,509 shares during the last quarter. PFM Health Sciences LP increased its position in shares of PMV Pharmaceuticals by 57.7% during the 3rd quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company's stock valued at $2,996,000 after purchasing an additional 735,578 shares during the last quarter. Finally, Sio Capital Management LLC raised its holdings in shares of PMV Pharmaceuticals by 18.7% during the 3rd quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company's stock valued at $4,789,000 after buying an additional 505,831 shares in the last quarter. Hedge funds and other institutional investors own 90.20% of the company's stock.

Wall Street Analyst Weigh In

Separately, Oppenheimer upgraded shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a research report on Friday, November 8th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, PMV Pharmaceuticals has an average rating of "Buy" and an average price target of $5.50.

PMV Pharmaceuticals Price Performance

PMV Pharmaceuticals stock traded down $0.03 during trading hours on Monday, reaching $1.39. The company had a trading volume of 64,988 shares, compared to its average volume of 151,108. PMV Pharmaceuticals, Inc. has a 12-month low of $1.32 and a 12-month high of $2.26. The firm has a market cap of $71.93 million, a price-to-earnings ratio of -1.39 and a beta of 1.46. The company has a 50-day moving average price of $1.46 and a 200 day moving average price of $1.53.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.